hf1k16
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 27, 2021 (NCT05386823)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Retinol-binding protein 1AGONIST
RBP1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05388487 | Phase 1 | Feb 16, 2022 | HighField Biopharmaceuticals Corporation, Huashan Hospital Shanghai, Tigermed Consulting Co., Ltd |
| NCT05386823 | Phase 1 | Mar 27, 2021 | Frontage Laboratories, Inc., HighField Biopharmaceuticals Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HighField Biopharmaceuticals Corporation | For profit | 2 | 2 | 1 | 2021 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Huashan Hospital Shanghai | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1